The Body Has a Built-In System That Fights Against Pain Relief — Mediated by Dynorphin
Dynorphin A(1-17) in the spinal cord actively opposes pain relief from most analgesics, functioning as an endogenous anti-painkiller that limits how effective pain drugs can be.
Quick Facts
What This Study Found
Dynorphin A(1-17) mediates an antianalgesic (pain-relief-opposing) system in the spinal cord. Most analgesics activate both pain relief and this dynorphin-mediated opposition simultaneously.
Key Numbers
How They Did This
Mice received intrathecal dynorphin antibodies followed by intracerebroventricular analgesic drugs. Pain was measured by tail-flick response. Multiple analgesic types were tested.
Why This Research Matters
This challenges the view that all opioid peptides are painkillers. Dynorphin A can oppose pain relief, which means the body has a built-in system that limits how much pain relief any drug can provide.
The Bigger Picture
This finding has profound implications for pain management. If the body automatically activates a dynorphin-mediated opposition to pain relief, then blocking this system could make existing painkillers more effective — potentially allowing lower doses. It also helps explain why chronic pain patients may develop tolerance: the anti-analgesic system may become hyperactive.
What This Study Doesn't Tell Us
Animal study in mice using spinal and brain injections. The very small doses active in the antianalgesic effect are unusual and the mechanism is not fully understood.
Questions This Raises
- ?Could blocking spinal dynorphin make pain medications more effective at lower doses?
- ?Is the dynorphin anti-analgesic system overactive in chronic pain patients?
Trust & Context
- Key Stat:
- Femtomole doses oppose pain relief Extremely small amounts of spinal dynorphin A(1-17) are sufficient to activate the antianalgesic system that limits pain drug effectiveness
- Evidence Grade:
- Preliminary animal study in mice using spinal and brain injections. The anti-analgesic concept is compelling but uses non-physiological drug delivery.
- Study Age:
- Published in 1990. The dynorphin anti-analgesic system has been further characterized and is now recognized as a factor in opioid tolerance and chronic pain.
- Original Title:
- Spinal dynorphin A (1-17): possible mediator of antianalgesic action.
- Published In:
- Neuropharmacology, 29(7), 609-17 (1990)
- Authors:
- Fujimoto, J M(2), Arts, K S, Rady, J J, Tseng, L F
- Database ID:
- RPEP-00155
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How can an opioid peptide oppose pain relief?
Not all opioid peptides reduce pain. Dynorphin A at very low doses in the spinal cord activates a descending pathway that counteracts analgesia. This is a natural regulatory mechanism that prevents the pain system from being completely shut off.
Could this help develop better pain medications?
Yes. If we can block the dynorphin anti-analgesic system, existing painkillers could become more effective at lower doses — potentially reducing side effects and addiction risk.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00155APA
Fujimoto, J M; Arts, K S; Rady, J J; Tseng, L F. (1990). Spinal dynorphin A (1-17): possible mediator of antianalgesic action.. Neuropharmacology, 29(7), 609-17.
MLA
Fujimoto, J M, et al. "Spinal dynorphin A (1-17): possible mediator of antianalgesic action.." Neuropharmacology, 1990.
RethinkPeptides
RethinkPeptides Research Database. "Spinal dynorphin A (1-17): possible mediator of antianalgesi..." RPEP-00155. Retrieved from https://rethinkpeptides.com/research/fujimoto-1990-spinal-dynorphin-a-117
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.